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Percutaneous coronary intervention, which was pioneered by Grüntzig in 1977, has become the most frequently performed therapeutic procedure in medicine.1 The use of balloon angioplasty, which was limited by 
abrupt vessel closure owing to dissections and restenosis, prompted the develop-
ment of stents to maintain lumen integrity.2 Coronary stents improved procedural 
safety and efficacy and eliminated the need for surgical standby.3 However, stent-
mediated arterial injury elicited neointimal hyperplasia, leading to restenosis and 
the need for repeat revascularization in up to one third of patients.4
Drug-eluting stents with controlled local release of antiproliferative agents have 
consistently reduced the risk of repeat revascularization, as compared with bare-
metal stents.5-7 However, a number of reports presented at the European Society 
of Cardiology Congress in 2006 questioned the long-term safety of drug-eluting 
stents, leading to a reduction in their use, along with intense review by regula-
tory agencies and recommendations to extend dual antiplatelet therapy for at least 
12 months.8-10 In 2007, the Journal published evidence that stents releasing sirolimus 
or paclitaxel, as compared with bare-metal stents, were associated with similar risks 
of death and myocardial infarction but with an increased, albeit small, risk of stent 
thrombosis beyond 1 year after stent implantation.8,11-14 Since then, new platforms 
for drug-eluting stents that are aimed at improving safety and efficacy have been 
developed. Drug-eluting stents are now implanted in more than 500,000 patients 
every year in the United States.15 This review provides an overview of currently avail-
able devices, summarizes evidence from randomized trials, and outlines clinical 
indications for use.
Pl atfor ms for Drug -Elu ting S ten t s
Drug-eluting stents have three components: a metallic stent platform, a polymer coat-
ing, and an antiproliferative agent (Fig. 1).
Stent Platforms
Available platforms are made of stainless steel, cobalt–chrome, or platinum–chrome. 
Cobalt–chrome alloys provide improved radial strength and increased radiopacity, as 
compared with stainless steel, allowing for engineering of thinner struts with 
greater deliverability. Platforms made with thinner struts may result in less arterial 
injury and reduce the risk of restenosis,16 with lower thrombogenicity.17 Platinum–
chrome alloys are used in an effort to further improve radial strength and conform-
ability.
Polymer Coatings
Polymer coatings that are applied to the stent surface serve as drug carriers and per-
mit controlled drug release. Progress in polymer technology has been aimed at 
decreasing local inflammatory reactions and thrombosis by improving the biocom-
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patibility of polymers.17,18 Drug-eluting stents 
that have been approved by the Food and Drug 
Administration (FDA) have durable polymer 
coatings (Table 1). However, new platforms for 
drug-eluting stents feature polymers that biode-
grade after drug elution, resulting in a stent sur-
face similar to that of a bare-metal stent.19 These 
new platforms have not yet been approved by the 
FDA but are commonly used in clinical practice 
outside the United States.
Antiproliferative Agents
Antiproliferative agents that are used for the 
platforms of drug-eluting stents are highly lipo-
philic molecules that are distributed into the ar-
terial wall and exert either immunosuppressive 
effects (inhibitors of mammalian target of rapa-
mycin) or antiproliferative effects (paclitaxel) on 
smooth-muscle cells (Fig. 1).
FDA-Approved Drug-Eluting Stents
Early-generation stents released sirolimus or pa-
clitaxel and had stainless-steel platforms, where-
as new-generation stents release everolimus or 
zotarolimus and feature cobalt–chrome or plati-
num–chrome platforms with thinner strut thick-
ness and more biocompatible, durable polymer 
coatings. These new-generation stents have al-
most completely replaced paclitaxel-eluting stents 
in clinical practice, and sirolimus-eluting stents 
are no longer manufactured.
Va scul a r Biol o gy
Arterial Healing after Stent Implantation
While providing inhibition of neointimal hyper-
plasia, drug-eluting stents should permit physi-
ological arterial healing with smooth and homo-
geneous endothelial coverage of all stent struts. 
This may be overbalanced by an excessive anti-
proliferative effect and persistence of stent compo-
nents (e.g., polymer coatings), leading to chronic 
inflammation and impaired arterial healing, with 
the attendant risk of thrombotic events (Fig. 2).20
Early-generation sirolimus- and paclitaxel-
eluting stents were associated with delayed arte-
rial healing — manifested as incomplete endo-
thelialization of stent struts, vessel remodeling, 
and persistent fibrin and platelet deposition20,21 
— and with premature neoatherosclerosis.22 
Improved endothelial coverage has been report-
ed after implantation of everolimus- and zotaro-
limus-eluting stents in studies in animals23 and 
in clinical studies with intracoronary imaging.24
Stent Thrombosis
Stent thrombosis, which is a rare but serious 
complication of treatment with both bare-metal 
stents and drug-eluting stents,25 has been related 
to procedural factors and inadequate platelet in-
hibition during the early postimplantation peri-
od, as well as to chronic inflammation and de-
layed arterial healing during late follow-up.25 
Early studies used different definitions of stent 
thrombosis, making comparisons across reports 
challenging. The Academic Research Consortium 
subsequently provided standardized criteria for 
the definition of stent thrombosis according to 
the time of occurrence (i.e., early, ≤1 month; late, 
>1 month to ≤1 year; or very late, >1 year) and the 
degree of diagnostic certainty (i.e., definite, prob-
able, or possible).26
Effic ac y a nd S a fe t y of Drug -
Elu ting S ten t s
Pivotal trials investigating drug-eluting stents are 
summarized in Table S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.
Stents Releasing Sirolimus or Paclitaxel
In a network meta-analysis7 (an analysis of stud-
ies of multiple interventions that makes use of 
direct and indirect comparison) involving 38 tri-
als and more than 18,000 patients, there was a 
marked reduction in the rate of repeat revascu-
larization with both sirolimus-eluting stents and 
paclitaxel-eluting stents, as compared with bare-
metal stents. On the basis of this analysis, 7 pa-
tients (95% confidence interval [CI], 6 to 8) 
would need to be treated with sirolimus-eluting 
stents and 8 patients (95% CI, 7 to 10) with pac-
litaxel-eluting stents in order to prevent one repeat 
revascularization, as compared with bare-metal 
stents. However, stents that release sirolimus or 
paclitaxel have been associated with an increased 
risk of very late stent thrombosis, as compared 
with bare-metal stents.11,27 In contrast, the risks of 
death and myocardial infarction with sirolimus-
eluting and paclitaxel-eluting stents were similar 
to the risks with bare-metal stents,7 which may 
be explained by the low incidence of very late 
stent thrombosis (annual rate, 0.2 to 0.6%) and 
the compensatory effects of a reduced risk of re-
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stenosis, which is manifested as myocardial in-
farction in 10 to 20% of patients.28,29
Everolimus-Eluting Stents
In randomized trials, everolimus-eluting stents 
improved clinical outcomes as compared with 
paclitaxel-eluting stents, reducing the risks of re-
peat revascularization, myocardial infarction, and 
stent thrombosis.30,31 Randomized comparisons 
showed similar outcomes for stents releasing 
everolimus and those releasing sirolimus with 
respect to rates of death, myocardial infarction, 
and repeat revascularization.32-34 A large trial 
showed lower rates of stent thrombosis with 
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everolimus-eluting stents than with sirolimus-
eluting stents at 2 years (0.2% vs. 0.9%, P = 0.02).33 
A recent network meta-analysis showed that 
everolimus-eluting stents, as compared with siro-
limus-eluting stents, may reduce the risk of stent 
thrombosis over the long term (relative risk, 0.37; 
95% CI, 0.20 to 0.66) and myocardial infarction 
(relative risk, 0.77; 95% CI, 0.64 to 0.95).35 How-
ever, the absence of differences with respect to 
ischemic outcomes in any of the individual trials 
allows no definitive conclusion regarding the 
comparative propensity for stent thrombosis with 
these two devices.
Zotarolimus-Eluting Stents
The Endeavor zotarolimus-eluting stent has been 
shown to reduce the risk of myocardial infarction 
Figure 1 (facing page). Components and Mechanisms 
of Action of Bare-Metal and Drug-Eluting Stents.
Shown are cross-sections and platforms of a bare-metal 
stent (Panel A) and a drug-eluting stent (Panel B). The 
implantation of a coronary-artery stent causes an arte-
rial injury that activates vascular smooth-muscle cells 
and leads to their migration and proliferation, with  
extracellular-matrix formation resulting in the produc-
tion of neointimal tissue. Excessive neointimal hyper-
plasia may lead to restenosis within the treated seg-
ment, with ischemia requiring repeat revascularization. 
Drug-eluting stents provide site-specific, controlled re-
lease of antiproliferative agents targeting the suppres-
sion of neointimal hyperplasia. These devices consist 
of three components: a metallic platform, a polymer 
coating that serves as drug carrier and permits con-
trolled drug release, and an antiproliferative agent. The 
antiproliferative agent is released over time, whereas 
the stent platform and the durable polymer coating re-
main in the coronary artery. New platforms for drug-
eluting stents — not yet approved by the Food and Drug 
Administration (FDA) but commonly used in clinical 
practice outside the United States — feature polymers 
that biodegrade after drug elution, resulting in a stent 
surface similar to that of a bare-metal stent. Antiprolifer-
ative agents used in FDA-approved drug-eluting stents 
and their mechanism of action are shown in Panel C. 
Most of the available drug-eluting stents use limus-fam-
ily analogues: sirolimus, everolimus, and zotarolimus. 
These agents bind to the intracellular receptor FKBP12, 
inhibiting the mammalian target of rapamycin (mTOR), 
which results in up-regulation of cyclin-dependent ki-
nase inhibitor p27Kip1. This blocks the proliferation of 
smooth-muscle cells in the gap 1 (G1) phase of the cell 
cycle. Conversely, paclitaxel binds to the β-tubulin sub-
unit of microtubules, inhibiting the disassembly of mi-
crotubules and thereby arresting cell replication in the 
G0–G1 and mitotic phases of the cycle of smooth-mus-
cle cells. MW denotes molecular weight.
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without compromising effectiveness, as compared 
with paclitaxel-eluting stents.36,37 A network meta-
analysis showed a lower risk of myocardial infarc-
tion with Endeavor zotarolimus-eluting stents, as 
compared with paclitaxel-eluting stents, over the 
long term (relative risk, 0.66; 95% CI, 0.53 to 0.86) 
and a similar risk of target-lesion revasculariza-
tion (relative risk, 1.14; 95% CI, 0.88 to 1.49).35
In the Patient-Related Outcomes with Endeav-
or versus Cypher Stenting Trial (PROTECT), in-
volving 8791 patients, investigators comparing 
Endeavor zotarolimus-eluting stents with siroli-
mus-eluting stents observed no difference in the 
primary end point of definite or probable stent 
thrombosis at 3 years.38 Similarly, the risk of 
death or myocardial infarction was similar with 
the two types of drug-eluting stents. Analyses of 
secondary outcomes showed a higher risk of 
repeat revascularization among patients treated 
with Endeavor zotarolimus-eluting stents than 
among those treated with sirolimus-eluting stents 
(5.6% vs. 3.5%, P<0.001), whereas patients treated 
with sirolimus-eluting stents had a higher risk 
of very late stent thrombosis (0.3% vs. 1.1%, 
P<0.001).38 These findings are consistent with 
previous randomized evidence.35
The Resolute zotarolimus-eluting stent was 
compared with the everolimus-eluting stent in two 
large-scale trials, which showed similar risks of 
cardiac death, myocardial infarction, repeat revas-
cularization, and stent thrombosis throughout a 
2-year period.39,40 Table 2 summarizes evidence 
from randomized trials of new-generation evero-
limus-eluting and zotarolimus-eluting stents.30-42
Indic ations for Use of Drug -
Elu ting S ten t s
Advantages and disadvantages of drug-eluting 
stents, bare-metal stents, and coronary-artery by-
pass surgery in various disorders are summarized 
in Table 3.
Stable Coronary Artery Disease
Drug-eluting stents appear to be effective and 
relatively safe in patients with stable coronary ar-
tery disease. The recent Fractional Flow Reserve 
versus Angiography for Multivessel Evaluation 2 
(FAME-2) trial compared revascularization with 
the use of drug-eluting stents followed by optimal 
medical therapy with medical therapy alone in 
patients with stable coronary artery disease and 
evidence of ischemia, as assessed by fractional 
flow reserve. The trial was stopped early by the 
data and safety monitoring board because of a 
markedly reduced need for urgent revasculariza-
tion in patients treated with drug-eluting stents, 
as compared with those who received optimal 
medical therapy alone (1.6% vs. 11.1%, P<0.001).43
The risk of death or myocardial infarction did not 
differ significantly between groups. It is note-
worthy that 50% of urgent revascularizations were 
triggered by myocardial infarction or unstable 
angina. According to the 2011 guidelines of the 
American College of Cardiology–American Heart 
Association for percutaneous coronary interven-
tions, use of drug-eluting stents has a class IA 
recommendation for patients undergoing elective 
percutaneous revascularization who are able to 
adhere to a prolonged regimen of dual antiplate-
let therapy.44
Acute Myocardial Infarction
Mechanical reperfusion with stent implantation 
represents the standard of care for patients with 
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Figure 2. Patterns of Healing after Implantation of a Coronary-Artery Stent.
The implantation of a coronary-artery stent can trigger three possible arterial 
healing patterns, as shown in the schematic representations, with corre-
sponding in vivo examples of images from intracoronary optical coherence 
tomography. Panel A shows excessive neointimal hyperplasia resulting in 
restenosis, observed in a patient 7 months after the implantation of a bare-
metal stent. Panel B shows delayed arterial healing with vessel remodeling 
and protruding stent struts, observed i  a patient 22 months after the im-
plantation of a sirolimus-eluting stent. Panel C shows physiological arterial 
healing, observed in a patient 18 months after the implantation of a biolimus-
eluting stent with a biodegradable polymer coating.
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acute infarction. Drug-eluting stents have been 
compared with bare-metal stents in several trials, 
which have shown similar risks of death and re-
infarction and a reduction in the risk of repeat 
revascularization. Fifteen patients (95% CI, 11 to 
27) would need to be treated with drug-eluting 
stents in order to prevent one repeat revasculariza-
tion, as compared with bare-metal stents (Table 
S2 in the Supplementary Appendix).45 However, 
the use of sirolimus-eluting and paclitaxel-eluting 
stents was associated with an increased risk of 
very late stent thrombosis.45 It has been specu-
lated that the large amount of intracoronary 
thrombus in patients with acute infarction may 
predispose them to stent malapposition — be-
cause of stent undersizing or thrombus resolu-
tion — and subsequently increased thromboge-
nicity.46 In addition, implantation of drug-eluting 
stents in ruptured plaques in patients with acute 
infarction has been associated with delayed arte-
rial healing.47
Recently, in the Evaluation of Xience-V Stent 
in Acute Myocardial Infarction (EXAMINATION) 
trial,41 everolimus-eluting stents were found not to 
be superior to bare-metal stents with respect to 
the composite end point of death, myocardial 
infarction, or any further revascularization among 
patients with acute infarction. However, evero-
limus-eluting stents reduced the risk of target-
lesion revascularization as well as stent throm-
bosis, as compared with bare-metal stents.41 
Long-term follow-up and larger trials that are 
powered for assessment of ischemic events will 
shed more light on the use of drug-eluting stents 
in patients with acute infarction. In such patients, 
the use of drug-eluting stents has a class IA recom-
mendation if patients are able to comply with a 
prolonged regimen of dual antiplatelet therapy.44
Diabetes
Patients with diabetes have a higher burden of 
atherosclerosis, smaller coronary arteries, and a 
higher risk of repeat revascularization after im-
plantation of a bare-metal stent than do patients 
without diabetes.48 Drug-eluting stents have been 
widely tested in patients with diabetes and have 
consistently reduced the rate of restenosis, as 
compared with bare-metal stents (Table S2 in the 
Supplementary Appendix). A network meta-analy-
sis49 involving 3852 patients with diabetes and 
10,947 patients without diabetes showed that drug-
eluting stents were as safe as bare-metal stents in 
patients with diabetes when dual antiplatelet 
therapy was prescribed for 6 months or more. In 
Table 3. Efficacy and Safety of Drug-Eluting Stents, Bare-Metal Stents, and Coronary-Artery Bypass Grafting (CABG), 
According to Clinical Indication.*
Outcome and Intervention
Stable Coronary
Artery Disease
Acute 
Myocardial
Infarction Diabetes
Multivessel
Disease
Left Main  
Coronary  
Artery Disease
Restenosis
Implantation of bare-metal stent + + + + +
Implantation of drug-eluting stent
Early-generation ++ ++ ++ ++ ++
New-generation +++ +++ ++ ++ [+] ++ [+]
CABG +++ – +++ +++ +++
Cardiac death, myocardial infarction, 
or stent thrombosis
Implantation of bare-metal stent + + + + +
Implantation of drug-eluting stent
Early-generation + +/– + + +
New-generation + [+] + [+] + + [+] ++ [+]
CABG + – ++ ++ ++
* Data are based on available findings from randomized clinical trials, with the use of bare-metal stents as the reference. 
(Results of these trials are summarized in Table S2 in the Supplementary Appendix.) For each listed clinical indication, 
the recommendation for the use of each type of stent or CABG is indicated by a symbol, with a minus sign (–) indicat-
ing a disadvantage; a plus sign indicating an advantage, with the number of plus signs (+, ++, or +++) indicating the 
degree of advantage; and a plus sign in brackets ([+]) indicating a potential advantage that is currently being tested in 
randomized, controlled trials.
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addition, the reduction in the risk of repeat revas-
cularization with the use of drug-eluting stents 
in patients with diabetes was similar to the risk 
reduction in patients without diabetes. According 
to current guidelines, diabetes is a condition in 
which the use of drug-eluting stents is preferable 
to the use of bare-metal stents.44 The selection of 
a specific type of drug-eluting stent in patients 
with diabetes is controversial.49-51
Multivessel Disease
Patients with complex multivessel coronary artery 
disease represent a high-risk subgroup. Angio-
plasty and implantation of bare-metal stents have 
been compared with bypass surgery in numerous 
randomized studies, as summarized in a system-
atic review that included 22 trials and in a pooled 
analysis involving 7812 patients from 10 trials.52,53 
Both analyses led to the conclusion that percuta-
neous and surgical revascularization strategies 
have similar outcomes with respect to rates of 
death and myocardial infarction. However, recur-
rent angina and repeat revascularization were more 
common among patients treated percutaneously, 
whereas stroke was more frequent among patients 
treated surgically.52,53
Three randomized trials have compared drug-
eluting stents with bypass surgery in patients 
with multivessel disease: the Coronary Artery 
Revascularization in Diabetes (CARDia) study,54 
the Future Revascularization Evaluation in Pa-
tients with Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease (FREEDOM) trial,55 
and the Synergy between Percutaneous Coronary 
Intervention with Taxus and Cardiac Surgery 
(SYNTAX) study56 (Table S2 in the Supplemen-
tary Appendix). In the CARDia trial, the use of 
percutaneous coronary intervention (with drug-
eluting stents used in 69% of procedures) was not 
shown to be noninferior to bypass surgery in 
patients with multivessel disease and diabetes, 
with respect to the composite end point of death, 
myocardial infarction, or stroke for a period of 
up to 5 years.54 The larger FREEDOM trial 
showed that revascularization with drug-eluting 
stents (predominantly stents releasing sirolimus 
or paclitaxel) was inferior to bypass surgery in 
patients with multivessel disease and diabetes, 
with respect to the composite end point of death, 
myocardial infarction, or stroke. Bypass surgery 
was associated with significantly reduced risks 
of death and myocardial infarction but a higher 
risk of stroke during the 5-year study. 
In the SYNTAX trial, the use of paclitaxel-
eluting stents was not shown to be noninferior 
to bypass surgery with respect to the composite 
end point of death, myocardial infarction, stroke, 
or repeat revascularization at 1 year in patients 
with multivessel and left main coronary artery 
disease.56 The rate of the primary end point at 
1 year was higher among patients treated with 
paclitaxel-eluting stents than among those treat-
ed with bypass surgery, mainly because of higher 
rates of repeat revascularization in the stent group. 
Conversely, stroke was more frequent among pa-
tients treated with bypass surgery. Five years of 
follow-up suggested that the rate of the primary 
end point continued to be higher among pa-
tients treated with paclitaxel-eluting stents than 
among those treated with bypass surgery (37.3% 
vs. 26.9%, P<0.001).57 Patients were stratified into 
three groups on the basis of the complexity of 
disease as seen on angiography according to a 
prespecified algorithm that assigned a SYNTAX 
score, ranging from 0 to 84, with higher scores 
indicating a greater complexity of disease. At 
5 years, the rate of the primary end point in the 
stent group was similar to that in the surgery 
group among patients with a low complexity of 
disease (SYNTAX score, ≤22; 32.1% and 28.6%, 
respectively; P = 0.43), whereas the benefit of 
bypass surgery emerged among patients with 
either intermediate disease complexity (SYNTAX 
score, 23 to 32; 36.0% vs. 25.8%; P = 0.008) or 
high disease complexity (SYNTAX score, ≥33; 
44.0% vs. 26.8%; P<0.001).57 These findings are 
hypothesis generating, and whether outcomes 
may be improved with the use of new-generation 
drug-eluting stents is a matter of debate. How-
ever, bypass surgery remains the treatment of 
choice for patients with the most extensive, com-
plex multivessel disease.44 A discussion by a 
multidisciplinary heart team composed of an 
interventionalist and a surgeon is recommended 
for such patients (class IC).44
Left Main Coronary Artery Disease
In the Premier of Randomized Comparison of By-
pass Surgery versus Angioplasty Using Sirolimus-
Eluting Stent in Patients with Left Main Coronary 
Artery Disease (PRECOMBAT) trial, sirolimus-
eluting stents were shown to be noninferior to 
bypass surgery in patients with left main coro-
nary artery disease with respect to the composite 
end point of death, myocardial infarction, stroke, 
or target-vessel revascularization at 1 year (Table 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on March 25, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;3 nejm.org january 17, 2013262
S2 in the Supplementary Appendix).58 However, 
the trial was small and had a wide noninferiority 
margin, which precluded definitive conclusions. 
In the SYNTAX trial, randomization was stratified 
according to the presence or absence of left main 
coronary artery disease. Among 705 patients with 
left main coronary artery disease, the risk of the 
primary end point, as well as the risk of cardiac 
death or myocardial infarction, at 3 years in the 
group that received paclitaxel-eluting stents was 
similar to the risk in the group that underwent 
bypass surgery.59 Stroke occurred more frequent-
ly among patients treated with bypass surgery, 
whereas repeat revascularization occurred more 
frequently among patients treated with paclitaxel-
eluting stents. Everolimus-eluting stents are being 
compared with bypass surgery in the Evaluation 
of Xience Everolimus-Eluting Stent System versus 
Coronary Artery Bypass Surgery for Effectiveness 
of Left Main Revascularization (EXCEL) trial 
(ClinicalTrials.gov number, NCT01205776) in pa-
tients with left main coronary artery disease. Ac-
cording to guidelines, percutaneous revasculariza-
tion is a reasonable alternative to bypass surgery 
in selected patients with left main coronary ar-
tery disease (class IIaB).44
A n tipl atele t Ther a py
Dual antiplatelet therapy with aspirin and a P2Y12 
inhibitor reduces the risk of ischemic events after 
stent placement; however, the duration of thera-
py remains a matter of debate. Clopidogrel in ad-
dition to aspirin for at least 12 months has been 
shown to reduce the composite end point of 
death, myocardial infarction, or stroke, as com-
pared with aspirin alone, among patients with 
acute coronary syndromes.60 The more potent 
drugs prasugrel and ticagrelor have been shown 
to be superior to clopidogrel in patients present-
ing with acute coronary syndromes.61,62 However, 
long-term dual antiplatelet therapy significantly 
increases the risk of bleeding.60-62 Moreover, only 
a few patients included in these trials were treat-
ed with drug-eluting stents, and data providing 
guidance on the duration of therapy in patients 
undergoing elective coronary stenting are sparse. 
Current guidelines support a 12-month regimen 
of dual antiplatelet therapy in patients treated 
with drug-eluting stents (class IB)44 on the basis 
of observational data pointing to the risk of stent 
thrombosis after premature discontinuation of 
clopidogrel.10 A combined analysis of data from 
two trials, the Correlation of Clopidogrel Therapy 
Discontinuation in Real-World Patients Treated 
with Drug-Eluting Stent Implantation — Late Cor-
onary Arterial Thrombotic Events (REAL-LATE) 
study and the Evaluation of the Long-Term Safety 
after Zotarolimus-Eluting Stent, Sirolimus-Eluting 
Stent, or Paclitaxel-Eluting Stent Implantation for 
Coronary Lesions — Late Coronary Arterial Throm-
botic Events (ZEST-LATE) trial, suggests that a 
prolongation of dual antiplatelet therapy beyond 
12 months after implantation of drug-eluting 
stents does not reduce the risk of death or myo-
cardial infarction, as compared with the use of 
aspirin alone.63 In the Prolonging Dual Antiplate-
let Treatment after Grading Stent-Induced Intimal 
Hyperplasia (PRODIGY) trial, among patients who 
were treated with 6 months of dual antiplatelet 
therapy, the risk of the composite end point of 
death, myocardial infarction, or stroke was simi-
lar to that among patients receiving 24 months of 
therapy, but those receiving 6 months of therapy 
had a markedly reduced risk of bleeding.64 More-
over, a few observational studies have suggested 
that early discontinuation of dual antiplatelet 
therapy might be safe after the implantation of 
stents releasing either zotarolimus or everolim-
us.65,66 Overall, the available evidence is incon-
clusive, and large-scale comparisons of different 
durations of dual antiplatelet therapy are ongoing 
(NCT00977938, NCT00661206, and NCT00822536).
The antiplatelet-therapy regimen after implan-
tation of drug-eluting stents in patients taking 
oral anticoagulants is also debated because of 
the increased risk of bleeding in such patients. 
In the What Is the Optimal Antiplatelet and An-
ticoagulant Therapy in Patients with Oral Anti-
coagulation and Coronary Stenting (WOEST) 
trial,67 patients who received only clopidogrel in 
addition to oral anticoagulants had a reduced risk 
of bleeding at 1 year, as compared with those 
receiving triple therapy with aspirin, clopidogrel, 
and oral anticoagulants, and the study suggest-
ed that the less intensive therapy might provide 
adequate protection against thrombotic compli-
cations. However, larger studies are needed for 
definite conclusions.
Cos t-Effec ti v eness
A reduction in the rate of restenosis with the use 
of drug-eluting stents comes at the expense of 
increased device cost, as compared with bare-
metal stents. Several studies have recommended 
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restricting the use of drug-eluting stents to pa-
tients at increased risk for restenosis in order to 
balance the risk–benefit assessment with cost-
effectiveness.68,69 Reducing the use of drug-elut-
ing stents among patients at low risk for resteno-
sis may result in cost savings with a small effect 
on the rate of repeat revascularization.69,70 How-
ever, reimbursement systems vary widely, render-
ing cost-effectiveness analyses rarely applicable 
to different health care systems. In the United 
States, a reduction in the use of drug-eluting 
stents in 2007, as compared with a more liberal 
use of such stents in the period from 2004 
through 2006 (in 68% and 92% of procedures, 
respectively), was associated with a small in-
crease in the risk of repeat revascularization (4.1 to 
5.1%) and a modest reduction in costs ($400 per 
patient) over a period of 1 year.70 Nevertheless, a 
recent analysis of stent use in routine clinical prac-
tice in the United States showed that the higher 
cost of drug-eluting stents, as compared with 
bare-metal stents, was offset by lower costs of 
repeat revascularization procedures over a period 
of 3 years.71 Whether drug-eluting stents should 
be used with or without restriction remains a 
subject of debate, particularly in light of uncer-
tainty regarding the optimal duration of dual anti-
platelet therapy, which has a substantial effect on 
health care costs.71 Moreover, a reduction in costs 
with the use of everolimus-eluting stents, as com-
pared with paclitaxel-eluting stents, has recently 
been documented.72
Open Issues a nd Fu t ur e 
Dir ec tions
Safety of New Drug-Eluting Stents versus 
Bare-Metal Stents
Network meta-analyses of randomized studies 
indicate a lower risk of stent thrombosis with 
everolimus-eluting stents than with bare-metal 
stents.35,42 This potential benefit needs to be ad-
dressed in appropriately designed studies. How-
ever, the feasibility and cost-effectiveness of such 
trials is questionable owing to the exceedingly 
low incidence of stent thrombosis.
Biodegradable Polymer Stents
The use of drug-eluting stents that have been 
coated with biodegradable polymers, which are 
commonly used in clinical practice outside the 
United States, has been shown to improve long-
term safety and efficacy, as compared with the 
use of sirolimus-eluting stents.19,73 In two recent 
trials, drug-eluting stents with biodegradable-
polymer coatings improved safety, as compared 
with bare-metal stents, in patients with acute in-
farction,74 and provided outcomes similar to those 
with everolimus-eluting stents in patients with 
coronary artery disease at 1 year.75 Additional 
studies and longer-term follow-up are needed to 
address possible differences between these two 
technologies.
Fully Bioresorbable Scaffolds
Fully bioresorbable drug-eluting vascular scaf-
folds will soon be available for clinical use.76 Al-
though the concept is attractive, it remains to be 
determined whether these devices can outper-
form available drug-eluting stents with respect to 
safety and efficacy.
Conclusions
Drug-eluting stents mitigate the risk of resteno-
sis and thus represent an important advance in 
the percutaneous treatment of coronary artery 
disease. New drug-eluting stents with thin struts 
releasing limus-family analogues from durable 
polymers have further improved clinical out-
comes, as compared with early-generation stents 
releasing sirolimus or paclitaxel. The risk of stent 
thrombosis has become exceedingly low and no 
longer represents a limitation of the use of drug-
eluting stents. Notably, the improved safety pro-
file of new drug-eluting stents comes without 
compromising their effectiveness. Available evi-
dence supports the use of drug-eluting stents in 
most clinical settings without safety concerns, 
unless patients have contraindications to the use 
of dual antiplatelet therapy.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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